title: Cancer targeting using tumor suppressor genes.
abstract: Conventional cancer treatments include cytotoxic chemotherapies and radiotherapy, which result in significant collateral toxicities. The goal for future cancer treatments is to leverage improved understanding of cancer biology mechanisms and thereby develop targeted drugs that display exquisite tumor selectivity and avoid iatrogenic damage. In this review, we discuss the potential of tumor suppressor genes for development of cancer-selective drugs using the tumor suppressor p53 as an archetype.
authors.affiliation: Department of Clinical Research and Development, Introgen Research Institute, Introgen Therapeutics Inc., Houston, Texas 77030, USA. s.chada@introgen.com
authors.forename: Sunil
authors.initials: S
authors.lastname: Chada
authors.forename: Kerstin B
authors.initials: KB
authors.lastname: Menander
authors.forename: Dora
authors.initials: D
authors.lastname: Bocangel
authors.forename: Jack A
authors.initials: JA
authors.lastname: Roth
authors.forename: Rajagopal
authors.initials: R
authors.lastname: Ramesh
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000737:chemistry; D002289:Carcinoma, Non-Small-Cell Lung / Q000378:metabolism; D017024:Chemotherapy, Adjuvant / Q000379:methods; D016147:Genes, Tumor Suppressor; D016158:Genes, p53; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008175:Lung Neoplasms / Q000378:metabolism; D008954:Models, Biological; D009369:Neoplasms / Q000235:genetics* / Q000378:metabolism* / Q000628:therapy; D014765:Viral Vaccines / Q000494:pharmacology*
chemical_list: D000911:Antibodies, Monoclonal; D014765:Viral Vaccines; C512972:advexin